Cargando…
BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant
Better adjuvants are needed for vaccines against seasonal influenza. TLR7 agonists are potent activators of innate immune responses and thereby may be promising adjuvants. Among the imidazoquinoline compounds, 1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine (BBIQ) was reported to be a highly acti...
Autores principales: | Kaushik, Deepender, Dhingra, Simran, Patil, Madhuri T., Piplani, Sakshi, Khanna, Varun, Honda-Okubo, Yoshikazu, Li, Lei, Fung, Johnson, Sakala, Isaac G., Salunke, Deepak B., Petrovsky, Nikolai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482670/ https://www.ncbi.nlm.nih.gov/pubmed/32298200 http://dx.doi.org/10.1080/21645515.2019.1710409 |
Ejemplares similares
-
Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective
por: Baldwin, Jeremy, et al.
Publicado: (2021) -
Prediction of novel mouse TLR9 agonists using a random forest approach
por: Khanna, Varun, et al.
Publicado: (2019) -
Identification of a group of bisbenzylisoquinoline (BBIQ) compounds as ferroptosis inhibitors
por: Fan, Yipu, et al.
Publicado: (2022) -
Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (M(pro)) as Potential COVID-19 Therapies
por: Piplani, Sakshi, et al.
Publicado: (2022) -
Potential COVID-19 Therapies from Computational Repurposing of Drugs and Natural Products against the SARS-CoV-2 Helicase
por: Piplani, Sakshi, et al.
Publicado: (2022)